The Biostatistics/Data Management Center - Radiation Therapy Oncology Group (RTOG) will provide the centralized data management and biostatistical support for the chemoprevention study (Project 1) and develop a quantitative risk assessment model (Project 2). The nutritional, behavioral, and analytic chemistry data which are generated for Projects 1 and 2 will also be the responsibility of the RTOG Center. They will be integrated with the clinical data derived from the chemoprevention study for analyses. Although the final repository for all the data needed for the analyses of Project 2 and will be the RTOG Center, intermediate data collection and processing will be performed at the Biostatistics/Data Management Center - M.D. Anderson Cancer Center (MDACC). The functional tasks to be performed by the RTOG Center include: 1) biostatistical support; 2) standardization of mechanisms; 3) patient registration and randomization; 4) collection, review, and computerization of clinical data; 5) biological specimens: tracking their receipt, routing to the pertinent cores, and incorporating the results of the core's analyses; 6) monitoring the quality of the submitted clinical data; 7) toxicity surveillance; 8) on-site audits of the RTOG institutions and MDACC; 9) monitoring the progress of Projects 1 and 2 by preparation of semi-annual reports; 10) monitoring performance of the participating institutions annually. The RTOG Biostatistics/Data Management Center will utilize the resources of the American College of Radiology in Philadelphia where the data management and the biostatistical support for the RTOG studies are already provided. The staff of the RTOG Center has participated in the design, data collection and monitoring, analyses, and reporting of over 25 multi-center head and neck studies. The staff has experience in providing the data management and biostatistical support for nine intergroup studies in which two or more cancer cooperative groups have contributed patients. Ancillary studies that collect tissue material for central laboratory review in conjunction with RTOG clinical trials have also been supported by the staff.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA052051-05S1
Application #
5207639
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Hildebrandt, Michelle A T; Lippman, Scott M; Etzel, Carol J et al. (2012) Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18:3705-13
Lee, J Jack; Wu, Xifeng; Hildebrandt, Michelle A T et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4:185-93
Zhang, Xiaofan; Yang, Hushan; Lee, J Jack et al. (2010) MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31:2118-23
Wang, Jianming; Lippman, Scott M; Lee, J Jack et al. (2010) Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31:1755-61
Wu, Xifeng; Spitz, Margaret R; Lee, J Jack et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2:617-24
William Jr, William N; Lee, J Jack; Lippman, Scott M et al. (2009) High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2:22-6
Papadimitrakopoulou, Vassiliki A; Lee, J Jack; William Jr, William N et al. (2009) Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27:599-604
Kawaguchi, Hidetoshi; El-Naggar, Adel K; Papadimitrakopoulou, Vali et al. (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60
Wu, Xifeng; Gu, Jian; Dong, Qiong et al. (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194-201
Lippman, Scott M; Lee, J Jack (2006) Reducing the ""risk"" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66:2893-903

Showing the most recent 10 out of 91 publications